|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Corium International, Inc.
| | | Phone: | (650) 298-8255 | Fax: | (650) 298-8012 | Year Established: | 1995 | Ticker: | CORI | Exchange: | NASDAQ | Main Contact: | Joseph J. Sarret, M.D., J.D., CBO | | Other Contacts: | Tim Sweemer, CPA, Chief Accounting Officer and VP, Administration Bobby Singh, Ph.D., CTO & VP, R&D Robert Breuil, CFO Christina Dickerson, VP, Corporate Development Dan Arsulowicz, VP, GR Operations Peter Staple, President & CEO
| | Company Description | Corium International is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. | |
|
|
|
|
|